Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Aclaris, Ampio, Arch, Ascentage, Beigene, Bio-Thera, Curevac, Cynata, Edesa, Kyowa Kirin, Innovent, Kamada, Merck, Pear, PTC, Sanofi, Regeneron, Ultragenyx.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Acadia, Aribio, Ascentage, Ascletis, Biosig Technologies, Clover, Eli Lilly, Evelo, Evgen, FSD, Hua Medicine, Humanigen, Inflarx, Innovent, Kiniksa, Neuren, Remegen, Ridgeback, Sagimet.

Data presented at the American Association for Cancer Research.

BioWorld Asia briefs for June 16.

Data presented at the American Diabetes Association's 80th Scientific Sessions and the American Academy of Dermatology's annual meeting.

HONG KONG – Astellas Pharma Inc. reported positive results from phase III of its DOLOMITES study comparing the efficacy and safety of roxadustat to that of darbepoetin alfa in treating anemia in nondialysis-dependent, stage 3 to 5 chronic kidney disease (CKD) patients.

HONG KONG – India’s Ministry of Health and Family Welfare (MOHFW) has drafted rules for the manufacturing, import and the compassionate use of unapproved drugs in the treatment of patients.

BEIJING – Rare disease specialist Canbridge Pharmaceuticals Inc., of Beijing, said it is collaborating with the Horae Gene Therapy Center at the University of Massachusetts (UMass) Medical School to conduct gene therapy research with a focus on neuromuscular conditions.